Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents-Reference-Cited by-同舟云学术

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents

Published:2024-08-07 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Raddi Marco G.^ORCID,Bencini Sara,Peruzzi Benedetta,Mattiuz Giorgio,De Pourcq Sven^ORCID,Tanturli Michele^ORCID,Chapuis Nicolas^ORCID,Consagra Angela,Rigodanza Luca,Amato Cristina,Sanna Alessandro,Tofacchi Elena,Attardi Enrico^ORCID,Park Sophie,Kosmider Olivier,Annunziato Francesco^ORCID,Fontenay Michaela,Santini Valeria^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01112-9.pdf

Reference15 articles.

1. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99:1594–601.

2. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111:574–82.

3. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.

4. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200–28.

5. Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango OJE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:EVIDoa2200008.